SIR 2024
Interventional Oncology
Qasim Javed, MD
Resident Physician
NYU School of Medicine
Financial relationships: Full list of relationships is listed on the CME information page.
Bedros Teslakian, MD
Director of Clinical Translational Research
NYU Langone Health
Disclosure information not submitted.
In our experience to date we have follow-up on 7 patients with advanced metastatic disease to the lung. Three patients with colorectal cancer, one with renal cell and 3 with primary lung cancer. Our mean follow up time is 88.8 (+/- 16.3; median 85) days. Table 1 shows the responses (by RECIST 1.1) and cancer type for each patient. 28.6% (2/7) of patients showed partial response while 57.1% (4/7) showed stable disease. Only one patient showed evidence of progressive disease at these follow up.
In addition, the three patients with colorectal cancer has seen significant changes in their CEA as outlined in Table 2. After ablation there is a significant increase in the patients CEA levels which subsequently decrease. In the patient with progressive disease there is a subsequent increase in CEA suggesting progression.
Conclusion: Although extremely early, our experience with the use of PEF in patients in refractory metastatic disease to the lung, showed more than 50% of the patients with stable disease. Two patients showed evidence of an abscopal effect with greater than 30% decrease in sum of diameters at mean follow up time of 88 days. Further studies of this and other cohorts is necessary to better understand the impact of PEF on metastatic disease to the lung.